Posts Tagged: march-in rights


Property Rights and State AGs’ Assault on Remdesivir: A Conservative Perspective

By now, everyone in the IP arena has heard about the demands of more than 30 state and territorial attorneys general (AGs) regarding the promising COVID treatment remdesivir. …
By James Edwards
1 month ago 11

No, You Can’t March in On Remdesivir

One thing you should never say in 2020 is: "Well, at least things can't get any worse." They can and often do. The latest exhibit—in the intellectual …
By Joseph Allen
2 months ago 5

Don’t Let Life Sciences Innovation Become Another Coronavirus Casualty

With two-thirds of the world in lockdown and no clear way out of the novel coronavirus crisis, it’s increasingly obvious that biopharmaceutical innovation will play a …
By Stephen Ezell & Philip Stevens
5 months ago 4

Will Bayh-Dole Survive Its 40th Birthday?

Next year marks the 40th anniversary of the passage of the Bayh-Dole Act. With election day looming, 2020 is likely to be the most politically contentious year of …
By Joseph Allen
11 months ago 1

Bayh-Dole Rocks While the Critics Play the Same False Note

A just-released study co-sponsored by the Biotechnology Innovation Organization (BIO) and AUTM provides new evidence of the significant contribution academic patent licensing makes to the U.S. …
By Joseph Allen
1 year ago 0

Knowledge Ecology International Letter Misleads on March-In Rights

Recently, Knowledge Ecology International sent to Congress a letter objecting to the draft “Green Paper on Unleashing American Innovation” disseminated by the National Institute of Standards and …
By Frederick-Reinhart
1 year ago 10

The Washington Post Misses the Mark on March-In Rights

The National Institute of Standards and Technology recently indicated in its "Return on Investment Initiative draft green paper" that it would issue regulations effectively ending attempts to …
By Joseph Allen
1 year ago 2

Special Interests are Watching Academic Tech Transfer

The original motivation for the Bayh-Dole Act was to encourage the commercialization of academic innovation so that new technologies could be available for the benefit of all. …
By Nikki Borman
2 years ago 0

Examining the Truvada #BreakThePatent Debate: Gilead Responds

In July 2012, the U.S. Food and Drug Administration (FDA) first approved Truvada, an acquired immunodeficiency syndrome (AIDS) treatment manufactured by Gilead Sciences as a daily pre-exposure …
By Steve Brachmann
2 years ago 3